Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Receivables - Accured (2018 - 2020)

Marker Therapeutics (MRKR) has disclosed Receivables - Accured for 3 consecutive years, with $559.0 as the latest value for Q4 2020.

  • On a quarterly basis, Receivables - Accured fell 99.01% to $559.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $559.0, a 99.01% decrease, with the full-year FY2020 number at $559.0, down 99.01% from a year prior.
  • Receivables - Accured was $559.0 for Q4 2020 at Marker Therapeutics, up from $135.0 in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $112200.0 in Q1 2019 to a low of $135.0 in Q3 2020.
  • A 3-year average of $53511.6 and a median of $56189.0 in 2019 define the central range for Receivables - Accured.
  • Peak YoY movement for Receivables - Accured: tumbled 48.06% in 2019, then tumbled 99.83% in 2020.
  • Marker Therapeutics' Receivables - Accured stood at $108177.0 in 2018, then crashed by 48.06% to $56189.0 in 2019, then plummeted by 99.01% to $559.0 in 2020.
  • Per Business Quant, the three most recent readings for MRKR's Receivables - Accured are $559.0 (Q4 2020), $135.0 (Q3 2020), and $3440.0 (Q2 2020).